Evolved Enzymes for Cancer Therapeutics and Orthogonal Systems

It is interesting the selections did not lower the K[subscript M] for desthiobiotin and actually led to a less efficient enzyme. This is an example of how "you get what you select for".

Evolved Enzymes for Cancer Therapeutics and Orthogonal Systems

Evolved Enzymes for Cancer Therapeutics and Orthogonal Systems

Directed evolution has been explored for a long time. Various ideas, methods, have been shown to be feasible and successful in the enzyme field. We were interested in evolving enzymes for applications. Therefore, we evolved human cystathionine gamma-lyase (hCGL) and E. coli biotin ligase for therapeutic and biotechnology applications. Wild-type human cystathionine gamma-lyase does not have any methionine-degrading activity, unlike the high methionine-degrading abilities of bacterial methionine gamma-lyase (MGL) found in Pseudomonas putida. The ability to engineer hCGL to breakdown methionine can be a potential cancer treatment by targeting the methionine-dependent cancer cells. However, the methionine-degrading activity of previously engineered hCGL has only shown 1% activity compared to MGL, too low to be useful in practical cancer therapeutics. By using a combination of protein design and phylogenetic analysis, we further evolved hCGL to achieve a higher methionine-degrading activity, with one variant displaying as much as 7% activity compared to bacterial MGL, making it a more likely candidate in cancer treatment.In addition, it has been shown that new orthogonal pairs of biotin protein ligase and biotin have many biotechnology applications. Therefore, we have developed selection scheme for directing the evolution of E. coli biotin protein ligase (BPL, gene: BirA) via in vitro compartmentalization, and have altered the substrate specificity of BPL towards the utilization of the biotin analogue desthiobiotin. Following just 6 rounds of selection and amplification several variants that demonstrated higher activity with desthiobiotin were identified. The best variants from Round 6, BirA6−40 and BirA6−47, showed 17-fold and 10-fold higher activity, respectively, their abilities to use desthiobiotin as a substrate. Further characterization of BirA6−40 and the single substitution variant BirA[subscript M157T] revealed that they had 2- to 3-fold higher kcat values for desthiobiotin, and 3- to 4-fold higher K[subscript M] values. The k[subscript cat]/K[subscript M] values for these enzymes were around 0.7-fold that of BirA[subscript wt-]. It is interesting the selections did not lower the K[subscript M] for desthiobiotin and actually led to a less efficient enzyme. This is an example of how "you get what you select for". Because peptide:DNA conjugates were distributed such that there was on average one template or less per emulsion compartment there was selection only for the catalytic rate (k[subscript cat]) of desthiobiotinylation and not for turnover. Given these conditions, it might be anticipated that the peptide substrate, rather than desthiobiotin, should be bound better by the winning variants, and in fact BirA6−40 showed a reduced K[subscript M] value for BAP.

More Books:

Evolved Enzymes for Cancer Therapeutics and Orthogonal Systems
Language: en
Pages: 252
Authors: Wei-Cheng Lu
Categories:
Type: BOOK - Published: 2013 - Publisher:

Directed evolution has been explored for a long time. Various ideas, methods, have been shown to be feasible and successful in the enzyme field. We were interested in evolving enzymes for applications. Therefore, we evolved human cystathionine gamma-lyase (hCGL) and E. coli biotin ligase for therapeutic and biotechnology applications. Wild-type
Improving Cancer Therapeutics
Language: en
Pages: 166
Authors: Juki Wing Keung Ng
Categories: Cancer
Type: BOOK - Published: 2005 - Publisher:

Books about Improving Cancer Therapeutics
Prediction of Response in Cancer Therapy
Language: en
Pages: 298
Authors: Thomas C. Hall
Categories: Cancer
Type: BOOK - Published: 1971 - Publisher:

Books about Prediction of Response in Cancer Therapy
Compilation of Experimental Cancer Therapy Protocol Summaries
Language: en
Pages:
Authors: Thomas C. Hall
Categories: Cancer
Type: BOOK - Published: 1982 - Publisher:

Books about Compilation of Experimental Cancer Therapy Protocol Summaries
Engineering Ribonuclease-based Cancer Therapeutics
Language: en
Pages: 368
Authors: Thomas John Rutkoski
Categories: Cancer
Type: BOOK - Published: 2008 - Publisher:

Books about Engineering Ribonuclease-based Cancer Therapeutics

Popular All Time

The Hero Code
Fast Burn!
The 48 Laws of Power
The Subtle Art of Not Giving a F*ck
The Way of Integrity
The Four Agreements
You Are a Badass Every Day
Beyond Tidy
Think and Grow Rich
Say What You Mean
Alcoholics Anonymous, Fourth Edition
12 Rules for Life
Healing Is the New High
Manifest Your Desires
The Untethered Soul
How to win friends & influence people
How To Win Friends & Influence People
Quit Like a Woman